ロード中...
Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
BACKGROUND. Patients with previously untreated BRAF V600E mutation-positive melanoma in BREAK-3 showed a median overall survival (OS) of 18.2 months for dabrafenib versus 15.6 months for dacarbazine (hazard ratio [HR], 0.76; 95% confidence interval, 0.48–1.21). Because patients receiving dacarbazine...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492231/ https://ncbi.nlm.nih.gov/pubmed/26040620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0429 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|